Author： Brass Volker Blum Hubert E Moradpour Darius
Publisher： Informa Healthcare
ISSN： 1472-8222
Source： Expert Opinion on Therapeutic Targets, Vol.8, Iss.4, 2004-08, pp. : 295-307
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Chronic hepatitis C is a leading cause of liver cirrhosis and hepatocellular carcinoma worldwide. Recent progress in the understanding of the molecular virology of hepatitis C has allowed the identification of novel antiviral targets. Moreover, in vitro and in vivo model systems have been developed that allow the systematic evaluation of new therapeutic strategies. Exciting results from proof-of-concept clinical studies have now been reported for a specific hepatitis C virus serine protease inhibitor. These and other novel antiviral strategies may complement existing therapeutic modalities in the future.
Related content
By Narjes Frank Koch Uwe Steinkühler Christian
Expert Opinion on Investigational Drugs, Vol. 12, Iss. 2, 2003-02 ,pp. :
Access to resources
Recommend
Recent developments in hepatitis C antiviral research 1999 - 2000
By Reding M.
Expert Opinion on Therapeutic Patents, Vol. 10, Iss. 8, 2000-08 ,pp. :